Genetically driven CD39 expression shapes human tumor‐infiltrating CD8 + T‐cell functions
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetically driven
CD39
expression shapes human tumor‐infiltrating
CD8
+
T‐cell functions
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-06-02
DOI
10.1002/ijc.33131
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL-27 confers a protumorigenic activity of regulatory T cells via CD39
- (2019) Young-Jun Park et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis
- (2019) Ilenia Cammarata et al. JOURNAL OF AUTOIMMUNITY
- Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
- (2019) Ivan Perrot et al. Cell Reports
- The role of NK cells and CD39 in the immunological control of tumor metastases
- (2019) Haiyan Zhang et al. OncoImmunology
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
- (2019) Selena Vigano et al. Frontiers in Immunology
- Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
- (2019) Andrea Cossarizza et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- CD103+Tumor-Resident CD8+T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment
- (2018) Jarem Edwards et al. CLINICAL CANCER RESEARCH
- CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes
- (2018) Friederike Raczkowski et al. PLoS One
- Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
- (2018) Thomas Duhen et al. Nature Communications
- Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth
- (2018) Ilenia Pacella et al. Cancer Immunology Research
- Wnt3a/β-Catenin Signaling Conditions Differentiation of Partially Exhausted T-effector Cells in Human Cancers
- (2018) Valeria Schinzari et al. Cancer Immunology Research
- CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+T Cells—Response
- (2018) Fernando P. Canale et al. CANCER RESEARCH
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- (2018) Yannick Simoni et al. NATURE
- CD39+ regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function
- (2018) Filip Ahlmanner et al. Oncotarget
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- Expansion of activated regulatory T cells inversely correlates with clinical severity in septic neonates
- (2016) Eleonora Timperi et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals
- (2016) Fengqin Fang et al. Cell Reports
- Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape
- (2016) Itsaso Montalbán del Barrio et al. Journal for ImmunoTherapy of Cancer
- SnapShot: T Cell Exhaustion
- (2015) Kristen E. Pauken et al. CELL
- The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation
- (2015) Anne Rissiek et al. JOURNAL OF AUTOIMMUNITY
- CD8+CD103+Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
- (2015) Fayçal Djenidi et al. JOURNAL OF IMMUNOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- CD39 Expression Identifies Terminally Exhausted CD8+ T Cells
- (2015) Prakash K. Gupta et al. PLoS Pathogens
- Role of TGF-β Signaling in Generation of CD39+CD73+Myeloid Cells in Tumors
- (2014) Sergey V. Ryzhov et al. JOURNAL OF IMMUNOLOGY
- High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors
- (2014) Elisabet Aliagas et al. MEDIATORS OF INFLAMMATION
- Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
- (2014) J. Bastid et al. Cancer Immunology Research
- CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes
- (2013) Alessia Parodi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extracellular adenosine triphosphate and adenosine in cancer
- (2010) J Stagg et al. ONCOGENE
- CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis
- (2009) J. M. Fletcher et al. JOURNAL OF IMMUNOLOGY
- CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease
- (2009) D. J. Friedman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential ectonucleotidase expression in human bladder cancer cell lines
- (2009) Joséli Stella et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started